Encouraging Initial Data from Randomized SELECT-AML-1 Ph 2 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine Announced December 11, 2023
US FDA Accepts for Priority Review Application for Breyanzi (lisocabtagene maraleucel) for R/R CLL/SLL December 4, 2023
Supplemental BLA submitted to US FDA for obecabtagene autoleucel (obe-cel) for Patients with R/R Adult B-Cell ALL December 4, 2023
Successful Completion of Safety Cohort and Positive DSMB Results from TCB008’s Trial in AML Patients Announced November 15, 2023
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Ph 3 Study of Lisaftoclax + Acalabrutinib in 1L CLL/SLL Patients October 25, 2023
First Patient Dosed in the Registrational Ph 3 Study of Olverembatinib in 1L Ph+ ALL Patients October 25, 2023
BRUKINSA Receives Positive Recommendation from NICE in U.K. for Adult Patients with CLL October 25, 2023
Global Registrational Ph 3 Study of Lisaftoclax in 1L CLL/SLL Patients Approved by the China CDE October 25, 2023
Enrollment ex-China in Ph 3 REGAL Trial for Galinpepimut-S in AML Expected to be Completed in Nov 2023 October 18, 2023
First Subjects dosed in Ph 2 Portion of Trial Evaluating Annamycin + Cytarabine (Ara-C) for the Treatment of AML October 11, 2023
Ph 3 ENHANCE-2 study of magrolimab in patients with AML with TP53 mutations discontinued October 3, 2023
European Commission Approves Enrylaze for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma October 3, 2023
European Commission approved INAQOVI® (oral decitabine and cedazuridine) for 1L AML patients September 26, 2023
Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML September 19, 2023
